Gallium‐Magnesium Layered Double Hydroxide for Elevated Tumor Immunotherapy Through Multi‐Network Synergistic Regulation
Advanced Materials · 2025-05 · 37 (21)
DOI: 10.1002/adma.202501256 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 07.04.2025. Verfasst von Jia Tan und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, P.…. Hauptthemen laut MEDLINE: Gallium, Immunotherapy, Hydroxides, Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Development Planning Project of Jilin Province.
Abstract (Originalsprache)
Immunotherapeutic efficacy is often limited by poor immunogenicity, immunosuppressive tumor microenvironment (TME), and cytoprotective mechanisms, leading to low immune activation. To this end, here, L‐amino acid oxidase (LAAO) loaded gallium‐magnesium layered double hydroxide (MG‐LAAO) is prepared for significantly enhanced tumor immunotherapy through multi‐network synergistic regulation. First, MG‐LAAO induces tumor cell pyroptosis by initiating caspase‐1/GSDMD and caspase‐3/GSDME pathways, further triggering immunogenic cell death (ICD). Then the released Ga 3+ induces mitochondrial iron overload, resulting in ferroptosis. In addition, MG‐LAAO also hinders autophagy of tumor cells, and reshapes the immunosuppressive tumor microenvironment (TME) by neutralizing H + and inhibiting lactic acid accumulation, thus destroying the cytoprotective mechanism and avoiding immune escape. Furthermore, this multi‐network synergy further activates the cGAS‐STING signaling pathway, generating powerful antitumor immunotherapy. This work highlights the critical role of synergies between autophagy block, pyroptosis, ferroptosis, and ICD in tumor immunotherapy, demonstrating the important role of this multi‐network synergy in effectively overcoming immunosuppressive TME and enhancing immunogenicity. In particular, the mechanism of gallium‐induced pyroptosis is revealed for the first time, providing theoretical support for the design of new materials for tumor immunotherapy in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, P. R. China.
- School of Applied Chemistry and Engineering, University of Science and Technology of China, Hefei, 230026, P. R. China.
- Key Laboratory of Superlight Materials and Surface Technology of Ministry of Education, College of Material Sciences and Chemical Engineering, Harbin Engineering University, Harbin, 150001, P. R. China.
ORCID-Profile: Ping'an Ma, Jun Lin
Förderung
- National Natural Science Foundation of China
- Science and Technology Development Planning Project of Jilin Province
Zitieren
APA
Tan, J., Ding, B., Chen, H., Meng, Q., Li, J., Zhang, W., Yang, Z., Ma, X., Han, D., Yang, M., Zheng, P., Ma, P., & Lin, J. (2025). Gallium‐Magnesium Layered Double Hydroxide for Elevated Tumor Immunotherapy Through Multi‐Network Synergistic Regulation. Advanced Materials, 37(21). https://doi.org/10.1002/adma.202501256
Vancouver
Tan J, Ding B, Chen H, Meng Q, Li J, Zhang W, et al. Gallium‐Magnesium Layered Double Hydroxide for Elevated Tumor Immunotherapy Through Multi‐Network Synergistic Regulation. Advanced Materials. 2025;37(21). doi:10.1002/adma.202501256
BibTeX
@article{Tan2025,
author = {Tan, Jia and Ding, Binbin and Chen, Hao and Meng, Qi and Li, Jing and Zhang, Wenying and Yang, Zhuang and Ma, Xinyu and Han, Di and Yang, Mingkai and Zheng, Pan and Ma, Ping'an and Lin, Jun},
title = {Gallium‐Magnesium Layered Double Hydroxide for Elevated Tumor Immunotherapy Through Multi‐Network Synergistic Regulation},
journal = {Advanced Materials},
year = {2025},
volume = {37},
number = {21},
doi = {10.1002/adma.202501256}
}
EUVIMED